Developer docs
API playgroundTry for free, no card

Search company profiles

GRI Bio (Reverse Merger With Vallon Pharmaceuticals)

Full company profile

uuid0003vu8

Namestring
GRI Bio (Reverse Merger With Vallon Pharmaceuticals)
Websiteurl
vallon-pharma.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Philadelphia, Pennsylvania, United States. The company operated with a small team of 1–10 employees and was previously listed on NASDAQ under the ticker symbol VLON before being delisted. The company's principal public strategic action of record is its reverse merger with GRI Bio, which repositioned the combined entity.

Based on the limited information available, Vallon's operating footprint appears to be narrowly focused on early-stage drug development with no disclosed commercial products, revenue generation, or partnerships in the provided data. No specific therapeutic candidates, pipeline assets, mechanism-of-action details, or platform technology are described in the source material. The company's business model, pre-merger, would have been characteristic of a clinical-stage biopharmaceutical company reliant on capital markets funding rather than product revenue, though no funding rounds or financial details are disclosed in the available input.

Post-reverse-merger with GRI Bio, the surviving entity — GRI Bio — is described as a separate clinical/biotech venture. The provided source material does not specify GRI Bio's pipeline, indication focus, scientific platform, or any commercial-stage activity. As such, the combined company's competitive positioning, technology stack, and revenue mechanics cannot be characterized beyond the structural fact of the reverse merger itself.

Short descriptiontext

Vallon Pharmaceuticals is a Philadelphia-based clinical-stage biopharmaceutical company founded in 2018 that completed a reverse merger with GRI Bio and was previously NASDAQ-listed under ticker VLON.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceuticals, drug development, pharmaceutical research, biotech therapeutics, immune-mediated diseases
Industry1 code
1Genetic & Genomic Rare Disease Therapeutics
CodeHLAIAIAAPrimaryYes
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutic candidates, with GRI Bio entering via a reverse merger transaction. The company operates with a small team of 1-10 employees and is headquartered in Philadelphia, United States, focused on advancing drug candidates through preclinical and clinical development stages.

Differentiator
Functional benefit
Problem solved
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
1Boehringer Ingelheim
TypeBroad incumbent
Description

Large global pharmaceutical company with nintedanib (Ofev), a leading approved IPF therapy. Comparable as the dominant incumbent in the IPF therapeutic area where GRI Bio is positioned.

2Tvardi Therapeutics
TypeEmerging player
Description

Early-to-mid-stage clinical biopharmaceutical company developing therapies for fibrotic diseases including IPF. Comparable as an emerging small clinical-stage peer focused on pulmonary fibrosis.

3Endeavor BioMedicines
TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing a lead IPF program (talotrexin class / pipeline focused on fibrotic and inflammatory diseases). Comparable emerging small clinical-stage fibrosis peer.

4United Therapeutics
TypeBroad incumbent
Description

Established biopharmaceutical company with Tyvaso, a leading IPF/pulmonary hypertension therapy. Comparable as a large, profitable pulmonary-focused biopharma serving the same end disease areas.

5BridgeBio Pharma
TypeBroad incumbent
Description

Mid-clinical-stage biopharmaceutical company with programs in fibrotic disease. Comparable as a multi-asset clinical-stage platform with public-market capital structure pursuing rare disease therapeutics.

6Pliant Therapeutics
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapies for fibrotic diseases, with a lead IPF program. Closely comparable to GRI Bio as a similarly positioned small-cap clinical-stage fibrosis/inflammation asset developer.

7FibroGen
TypeDirect peer
Description

Clinical-stage biopharmaceutical company with pamrevlumab in IPF. Comparable as a focused fibrosis therapeutic developer with a public-market capital structure and Phase-stage pipeline asset.

8Galapagos NV
TypeBroad incumbent
Description

Clinical-stage biopharmaceutical company with historic IPF pipeline exposure. Comparable as a larger specialty biopharma with fibrosis/inflammation clinical programs and public-market scale.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GRI Bio (Reverse Merger With Vallon Pharmaceuticals)

Clinical-Stage Biopharmaceuticalsvallon-pharma.com

Vallon Pharmaceuticals is a Philadelphia-based clinical-stage biopharmaceutical company founded in 2018 that completed a reverse merger with GRI Bio and was previously NASDAQ-listed under ticker VLON.

What GRI Bio (Reverse Merger With Vallon Pharmaceuticals) does

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Philadelphia, Pennsylvania, United States. The company operated with a small team of 1–10 employees and was previously listed on NASDAQ under the ticker symbol VLON before being delisted. The company's principal public strategic action of record is its reverse merger with GRI Bio, which repositioned the combined entity.

Based on the limited information available, Vallon's operating footprint appears to be narrowly focused on early-stage drug development with no disclosed commercial products, revenue generation, or partnerships in the provided data. No specific therapeutic candidates, pipeline assets, mechanism-of-action details, or platform technology are described in the source material. The company's business model, pre-merger, would have been characteristic of a clinical-stage biopharmaceutical company reliant on capital markets funding rather than product revenue, though no funding rounds or financial details are disclosed in the available input.

Post-reverse-merger with GRI Bio, the surviving entity — GRI Bio — is described as a separate clinical/biotech venture. The provided source material does not specify GRI Bio's pipeline, indication focus, scientific platform, or any commercial-stage activity. As such, the combined company's competitive positioning, technology stack, and revenue mechanics cannot be characterized beyond the structural fact of the reverse merger itself.

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) firmographics

Firmographics
Name
GRI Bio (Reverse Merger With Vallon Pharmaceuticals)
Website
https://vallon-pharma.com
Company type
Private
Founded year
2018
Headcount range
1–10 employees
Short description
Vallon Pharmaceuticals is a Philadelphia-based clinical-stage biopharmaceutical company founded in 2018 that completed a reverse merger with GRI Bio and was previously NASDAQ-listed under ticker VLON.
Ownership category
akta.pro rank

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

  • Clinical-stage biopharmaceuticals
  • Drug development
  • Pharmaceutical research
  • Biotech therapeutics
  • Immune-mediated diseases

Where GRI Bio (Reverse Merger With Vallon Pharmaceuticals) is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) product offering

Product offering

Core offering

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutic candidates, with GRI Bio entering via a reverse merger transaction. The company operates with a small team of 1-10 employees and is headquartered in Philadelphia, United States, focused on advancing drug candidates through preclinical and clinical development stages.

Differentiator

Problem solved

Functional benefit

Companies that use GRI Bio (Reverse Merger With Vallon Pharmaceuticals)

Customer profile

Ideal customer profiles1 record

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights1 record

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) competitors and assessment

Company assessment

Broad incumbents

  • Boehringer Ingelheim: Large global pharmaceutical company with nintedanib (Ofev), a leading approved IPF therapy. Comparable as the dominant incumbent in the IPF therapeutic area where GRI Bio is positioned.
  • United Therapeutics: Established biopharmaceutical company with Tyvaso, a leading IPF/pulmonary hypertension therapy. Comparable as a large, profitable pulmonary-focused biopharma serving the same end disease areas.
  • BridgeBio Pharma: Mid-clinical-stage biopharmaceutical company with programs in fibrotic disease. Comparable as a multi-asset clinical-stage platform with public-market capital structure pursuing rare disease therapeutics.
  • Galapagos NV: Clinical-stage biopharmaceutical company with historic IPF pipeline exposure. Comparable as a larger specialty biopharma with fibrosis/inflammation clinical programs and public-market scale.

Emerging players

  • Tvardi Therapeutics: Early-to-mid-stage clinical biopharmaceutical company developing therapies for fibrotic diseases including IPF. Comparable as an emerging small clinical-stage peer focused on pulmonary fibrosis.
  • Endeavor BioMedicines: Clinical-stage biopharmaceutical company developing a lead IPF program (talotrexin class / pipeline focused on fibrotic and inflammatory diseases). Comparable emerging small clinical-stage fibrosis peer.

Direct peers

  • Pliant Therapeutics: Clinical-stage biopharmaceutical company developing therapies for fibrotic diseases, with a lead IPF program. Closely comparable to GRI Bio as a similarly positioned small-cap clinical-stage fibrosis/inflammation asset developer.
  • FibroGen: Clinical-stage biopharmaceutical company with pamrevlumab in IPF. Comparable as a focused fibrosis therapeutic developer with a public-market capital structure and Phase-stage pipeline asset.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) social profiles

Digital presence

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) leadership team

Management profile

Number of profiles

Profiles1 record

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GRI Bio (Reverse Merger With Vallon Pharmaceuticals)

What does GRI Bio (Reverse Merger With Vallon Pharmaceuticals) do?

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutic candidates, with GRI Bio entering via a reverse merger transaction. The company operates with a small team of 1-10 employees and is headquartered in Philadelphia, United States, focused on advancing drug candidates through preclinical and clinical development stages.

When was GRI Bio (Reverse Merger With Vallon Pharmaceuticals) founded?

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) was founded in 2018. It employs 1 to 10 people.

Where is GRI Bio (Reverse Merger With Vallon Pharmaceuticals) based?

GRI Bio (Reverse Merger With Vallon Pharmaceuticals) is headquartered in Philadelphia, United States, in the North America region.

Who are GRI Bio (Reverse Merger With Vallon Pharmaceuticals)'s main competitors?

Broad incumbents on record are Boehringer Ingelheim, United Therapeutics, BridgeBio Pharma and Galapagos NV. Emerging players are Tvardi Therapeutics and Endeavor BioMedicines. Direct peers are Pliant Therapeutics and FibroGen.

Does GRI Bio (Reverse Merger With Vallon Pharmaceuticals) have an API?

No public API is recorded for GRI Bio (Reverse Merger With Vallon Pharmaceuticals).

What industry is GRI Bio (Reverse Merger With Vallon Pharmaceuticals) in?

GRI Bio (Reverse Merger With Vallon Pharmaceuticals)'s product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial OfficerGRI Bio appointed Leanne Kelly as Chief Financial Officer, bringing over 20 years of finance experience. Kelly previously served as CFO of Vallon Pharmaceuticals, which recently merged with GRI Bio. She will help guide the company's transition to public markets.GlobeNewswireVallon Pharmaceuticals Completes Merger with GRI Bio, Inc.GRI Bio, Inc. has completed its merger with Vallon Pharmaceuticals, resulting in the combined entity operating under the GRI Bio name and trading on Nasdaq under the ticker symbol "GRI" starting April 24, 2023. The transaction included a $15 million investment from Altium Capital to fund the company's pipeline of NKT modulating therapies for inflammatory and autoimmune diseases through mid-2024.GlobeNewswireVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023Vallon Pharmaceuticals adjourned its special stockholder meeting to April 20, 2023, to give shareholders more time to vote on the proposed merger with GRI Bio. The board unanimously recommends voting FOR the merger proposals, and stockholders of record as of March 6, 2023, are entitled to vote.BenzingaIs Vallon Pharmaceuticals Inc (VLON) recent surge justified - AMTD IDEA (NYSE:AMTD)Vallon Pharmaceuticals Inc (VLON) experienced a significant stock price surge of 72.57% to close at $0.4625, followed by an additional 25.41% gain in after-hours trading with over 127 million shares traded. The article also lists AMTD IDEA Group and Bright Green Corporation as other notable stocks to watch. The content includes promotional material for InvestorBrandMedia's ticker tagging services.PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds MLVF, VLON, APEN, and HZN Shareholders About Its Ongoing InvestigationsWeiss Law announced ongoing investigations into four separate proposed mergers and acquisitions for possible breaches of fiduciary duty: the acquisition of Malvern Bancorp, Inc. by First Bank (0.7733 shares plus $7.80 cash per share), the reverse merger of Vallon Pharmaceuticals, Inc. with GRI Bio, Inc., the acquisition of Apollo Endosurgery, Inc. by Boston Scientific Corporation ($10.00 cash per share), and the tender offer acquisition of Horizon Global Corporation by First Brands Group, LLC ($1.75 cash per share).PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and MTCR Shareholders About Its Ongoing InvestigationsWeiss Law is investigating potential breaches of fiduciary duty and legal violations by the boards of four companies in connection with their proposed mergers or acquisitions. The companies involved include Sesen Bio, Malvern Bancorp, Vallon Pharmaceuticals, and Metacrine, each of which is undergoing significant corporate transactions that will affect shareholder rights and value.PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates Vallon Pharmaceuticals, Inc.Weiss Law has announced an investigation into possible breaches of fiduciary duty by the board of directors of Vallon Pharmaceuticals, Inc. in connection with a proposed merger with GRI Bio, Inc. Under the merger agreement, Vallon will acquire 100% of GRI Bio's equity through a reverse triangular merger, resulting in Vallon shareholders owning approximately 17% of the combined company while GRI Bio shareholders retain approximately 83%. The law firm is examining whether the board acted in shareholders' best interests and whether the merger consideration adequately compensates Vallon shareholders.BenzingaWhy Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday's Mid-Day SesThe article lists numerous stocks moving in Wednesday's mid-day session, highlighting significant gains for companies such as Crown ElectroKinetics and Vallon Pharmaceuticals, alongside losses for entities like Netcapital and Drive Shack. Key corporate developments include merger agreements, clinical trial results, regulatory decisions, and financial reporting that drove these price movements. The content serves as a market summary rather than focusing on a single specific event.BenzingaWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket -The article presents a list of various stocks moving in pre-market trading, highlighting significant percentage changes for multiple companies. Key events include Vallon Pharmaceuticals rising over 150% due to a merger agreement with GRI Bio, and Clovis Oncology initiating Chapter 11 bankruptcy proceedings despite a price increase. Other notable movements involve voluntary delistings by Drive Shack and Rubicon Technology, and acquisitions by BIMI International Medical.BenzingaVallon Pharmaceuticals Stock Just Doubled In After Hours: Here's WhyVallon Pharmaceuticals entered into a definitive merger agreement with privately held biotechnology company GRI Bio in an all-stock transaction. The combined entity, which will operate under the name GRI Bio Inc and be listed on Nasdaq, is supported by a $15 million initial investment from Altium Capital with an additional $10 million committed for the future.